Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia.
Saved in:
| Title: | Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in Colombia. |
|---|---|
| Authors: | Guevara-Cuellar CA; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. Electronic address: cguevara@icesi.edu.co., Parody-Rúa E; Weber, Pharmacoeconomics and Market Access Department, Madrid, España., Rengifo-Mosquera MP; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia., Del Mar Conde-Crespo M; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia., Nuñez-Castro JM; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia. |
| Source: | Value in health regional issues [Value Health Reg Issues] 2022 Nov; Vol. 32, pp. 109-118. Date of Electronic Publication: 2022 Sep 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101592642 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-1102 (Electronic) Linking ISSN: 22121099 NLM ISO Abbreviation: Value Health Reg Issues Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2212-1102 |
|---|---|
| DOI: | 10.1016/j.vhri.2022.08.002 |
